SEC Form 4 · accession 0001250853-18-000067
Kindred Biosciences, Inc. · KIN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ernest Mario
Director
Period of report
Apr 20, 2018
Accepted (ET)
Apr 24, 2018 · 8:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001561743
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $9.65 | Apr 20, 2018 | A | 44,603 | A | — | Apr 19, 2028 | Common Stock | 44,603 | 44,603 | D |
Explanation of responses
- F1The option will vest in four quarterly installments following April 2, 2018.